NASDAQ:CRBU
Caribou Biosciences, Inc.
Caribou Biosciences, Inc.'s revenue grew 11.7% in fiscal 2025 to $11.2M while operating margin rose to −1329.4%. Free cash flow was −$112.4M, −1006.8% of revenue, and the diluted share count rose 3.4%.Summary generated from Caribou Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$11.2M
Revenue growth+11.7%
Revenue, 5-yr CAGR−2.0%
Gross marginn/a
Operating margin−1329.4%
Net margin−1327.4%
ROICn/a
Return on equity−79.0%
Debt / equityn/a
Free cash flow−$112.4M
FCF margin−1006.8%
Share count change+3.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 10 | 14 | 34 | 10 | 11 |
| Operating income | −67 | −106 | −116 | −167 | −148 |
| Net income | −67 | −99 | −102 | −149 | −148 |
| Free cash flow | −35 | −97 | −105 | −143 | −112 |
Recent filings
- 8-KCosts of exit or disposal activities
Oct 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KResults of a shareholder vote
Jun 18, 2026 - 8-KRegulation FD disclosure
Jun 11, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - DEF 14AProxy statement
Apr 24, 2026